AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]

Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Metho...

Full description

Bibliographic Details
Main Authors: Shennan Aibel Weiss, Ali A Asadi-Pooya, Sitaram Vangala, Stephanie Moy, Dale H Wyeth, Iren Orosz, Michael Gibbs, Lara Schrader, Jason Lerner, Christopher K Cheng, Edward Chang, Rajsekar Rajaraman, Inna Keselman, Perdro Churchman, Christine Bower-Baca, Adam L Numis, Michael G Ho, Lekha Rao, Annapoorna Bhat, Joanna Suski, Marjan Asadollahi, Timothy Ambrose, Andres Fernandez, Maromi Nei, Christopher Skidmore, Scott Mintzer, Dawn S Eliashiv, Gary W Mathern, Marc R Nuwer, Michael Sperling, Jerome Engel Jr, John M Stern
Format: Article
Language:English
Published: F1000 Research Ltd 2017-04-01
Series:F1000Research
Subjects:
Online Access:https://f1000research.com/articles/6-30/v2
id doaj-6e900f7054d147ec93446194a75c468f
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Shennan Aibel Weiss
Ali A Asadi-Pooya
Sitaram Vangala
Stephanie Moy
Dale H Wyeth
Iren Orosz
Michael Gibbs
Lara Schrader
Jason Lerner
Christopher K Cheng
Edward Chang
Rajsekar Rajaraman
Inna Keselman
Perdro Churchman
Christine Bower-Baca
Adam L Numis
Michael G Ho
Lekha Rao
Annapoorna Bhat
Joanna Suski
Marjan Asadollahi
Timothy Ambrose
Andres Fernandez
Maromi Nei
Christopher Skidmore
Scott Mintzer
Dawn S Eliashiv
Gary W Mathern
Marc R Nuwer
Michael Sperling
Jerome Engel Jr
John M Stern
spellingShingle Shennan Aibel Weiss
Ali A Asadi-Pooya
Sitaram Vangala
Stephanie Moy
Dale H Wyeth
Iren Orosz
Michael Gibbs
Lara Schrader
Jason Lerner
Christopher K Cheng
Edward Chang
Rajsekar Rajaraman
Inna Keselman
Perdro Churchman
Christine Bower-Baca
Adam L Numis
Michael G Ho
Lekha Rao
Annapoorna Bhat
Joanna Suski
Marjan Asadollahi
Timothy Ambrose
Andres Fernandez
Maromi Nei
Christopher Skidmore
Scott Mintzer
Dawn S Eliashiv
Gary W Mathern
Marc R Nuwer
Michael Sperling
Jerome Engel Jr
John M Stern
AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
F1000Research
Neuroimaging
author_facet Shennan Aibel Weiss
Ali A Asadi-Pooya
Sitaram Vangala
Stephanie Moy
Dale H Wyeth
Iren Orosz
Michael Gibbs
Lara Schrader
Jason Lerner
Christopher K Cheng
Edward Chang
Rajsekar Rajaraman
Inna Keselman
Perdro Churchman
Christine Bower-Baca
Adam L Numis
Michael G Ho
Lekha Rao
Annapoorna Bhat
Joanna Suski
Marjan Asadollahi
Timothy Ambrose
Andres Fernandez
Maromi Nei
Christopher Skidmore
Scott Mintzer
Dawn S Eliashiv
Gary W Mathern
Marc R Nuwer
Michael Sperling
Jerome Engel Jr
John M Stern
author_sort Shennan Aibel Weiss
title AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
title_short AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
title_full AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
title_fullStr AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
title_full_unstemmed AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
title_sort ar2, a novel automatic muscle artifact reduction software method for ictal eeg interpretation: validation and comparison of performance with commercially available software [version 2; referees: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2017-04-01
description Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p<0.01). Fewer readers could lateralize seizure-onset (p<0.05). The confidence measures of the assignments were low (probable-unlikely), but increased using AR2 (p<0.05). The ICC for identifying the time of seizure-onset was 0.15 (95% confidence interval (CI), 0.11-0.18) using AR1 and 0.26 (95% CI 0.21-0.30) using AR2.  The EEG interpretations were often consistent with behavioral, neurophysiological, and neuro-radiological findings, with left sided assignments correct in 95.9% (CI 85.7-98.9%, n=4) of cases using AR2, and 91.9% (77.0-97.5%) (n=4) of cases using AR1. Conclusions: EEG artifact reduction methods for localizing seizure-onset does not result in high rates of interpretability, reader confidence, and inter-reader agreement. However, the assignments by groups of readers are often congruent with other clinical data. Utilization of the AR2 software method may improve the validity of ictal EEG artifact reduction.
topic Neuroimaging
url https://f1000research.com/articles/6-30/v2
work_keys_str_mv AT shennanaibelweiss ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT aliaasadipooya ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT sitaramvangala ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT stephaniemoy ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT dalehwyeth ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT irenorosz ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT michaelgibbs ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT laraschrader ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT jasonlerner ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT christopherkcheng ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT edwardchang ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT rajsekarrajaraman ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT innakeselman ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT perdrochurchman ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT christinebowerbaca ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT adamlnumis ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT michaelgho ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT lekharao ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT annapoornabhat ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT joannasuski ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT marjanasadollahi ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT timothyambrose ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT andresfernandez ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT marominei ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT christopherskidmore ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT scottmintzer ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT dawnseliashiv ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT garywmathern ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT marcrnuwer ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT michaelsperling ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT jeromeengeljr ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
AT johnmstern ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftwareversion2referees2approved
_version_ 1724748355772350464
spelling doaj-6e900f7054d147ec93446194a75c468f2020-11-25T02:48:21ZengF1000 Research LtdF1000Research2046-14022017-04-01610.12688/f1000research.10569.212199AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software [version 2; referees: 2 approved]Shennan Aibel Weiss0Ali A Asadi-Pooya1Sitaram Vangala2Stephanie Moy3Dale H Wyeth4Iren Orosz5Michael Gibbs6Lara Schrader7Jason Lerner8Christopher K Cheng9Edward Chang10Rajsekar Rajaraman11Inna Keselman12Perdro Churchman13Christine Bower-Baca14Adam L Numis15Michael G Ho16Lekha Rao17Annapoorna Bhat18Joanna Suski19Marjan Asadollahi20Timothy Ambrose21Andres Fernandez22Maromi Nei23Christopher Skidmore24Scott Mintzer25Dawn S Eliashiv26Gary W Mathern27Marc R Nuwer28Michael Sperling29Jerome Engel Jr30John M Stern31Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartments of Neurosurgery, Psychiatry, and Biobehavioral Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USADepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USAObjective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p<0.01). Fewer readers could lateralize seizure-onset (p<0.05). The confidence measures of the assignments were low (probable-unlikely), but increased using AR2 (p<0.05). The ICC for identifying the time of seizure-onset was 0.15 (95% confidence interval (CI), 0.11-0.18) using AR1 and 0.26 (95% CI 0.21-0.30) using AR2.  The EEG interpretations were often consistent with behavioral, neurophysiological, and neuro-radiological findings, with left sided assignments correct in 95.9% (CI 85.7-98.9%, n=4) of cases using AR2, and 91.9% (77.0-97.5%) (n=4) of cases using AR1. Conclusions: EEG artifact reduction methods for localizing seizure-onset does not result in high rates of interpretability, reader confidence, and inter-reader agreement. However, the assignments by groups of readers are often congruent with other clinical data. Utilization of the AR2 software method may improve the validity of ictal EEG artifact reduction.https://f1000research.com/articles/6-30/v2Neuroimaging